Press Releases

• Accent Therapeutics: First Patient Dosed in Phase 1/2 Trial of Novel KIF18A Inhibitor ATX-295 and Receives FDA Fast Track Designation for Lead Assets ATX-295 and DHX9 Inhibitor ATX-559 More
• Biogen: Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission More
• Cellino: Partnership With Karis Bio to Develop First Nebula-Powered Autologous iPSC Therapy for Cardiovascular Disease More
• Dyne Therapeutics: Chief Business Officer and Chief Scientific Officer Appointments More
• eGenesis and OrganOx: U.S. FDA Clearance of IND Application for the Treatment of Patients With Acute-On-Chronic Liver Failure More More*
• FluidForm Bio: Advances Vascularized Tissue Engineering With New FRESH 3D Bioprinting Breakthrough More
• Inhibikase Therapeutics: Appointment of David McIntyre as Chief Financial Officer More
• MetaVia: Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability More
• Oak Hill Bio: Enters Into Exclusive License Agreement With Roche to Obtain Global Rights for a Phase 3-Ready, Potential Best-in-Class Treatment for Individuals With Angelman Syndrome More More*
• ProQR: Strengthens Leadership With Appointments of CFO and CMO to Support Next Phase of Growth More
• Remix Therapeutics: Appoints Linda C. Bain to Board of Directors More
• SCIEX: Appoints Chris Hagen as President More
• Sumitomo Pharma America: Enters Into a Cooperative Research and Development Agreement With the National Cancer Institute to Advance Clinical Understanding of Enzomenib More
• Thermo Fisher Scientific; Introduces the 5L DynaDrive Single-Use Bioreactor to Simplify and Accelerate Process Development and Help Bring Therapies to Market Faster More

Financial News

• At Harvard, Scientists Worry Over the Consequences of Resisting the Trump Administration: $2.2B in Grants Frozen More* More*
  
• Boehringer Ingelheim and Cue Biopharma: Partner to Develop Next-Generation Treatment for Autoimmune and Inflammatory Diseases More More
  
• Cue Biopharma: Pricing of Approximately $20 Million Public Offering More
• Dyne Therapeutics: Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) More
• Neuphoria: Review of 2024 and Highlights 2025 Plans More
• 908 Devices: Preliminary First Quarter 2025 Financial Results More
  
• Siddhartha Mukherjee’s Cell Therapy Startup Narrows Focus as Staff Shrinks More*
• Understanding the True Risk of Biotech Shareholder Lawsuits Podcast

Media/Misc Coverage

• BiotechTV: After Switching to a New GalNAc-LNP Delivery Vehicle a Year Ago, Verve Therapeutics Today Announced the Initial Safety and Efficacy Data From Its Verve-102 PCSK9 Base Editor Video More* More
• Dana-Farber: Researchers Receive AACR 2025 Scientific Achievement Awards More
• Dana-Farber: Years of Research Help Forge a New Path in Hodgkin Lymphoma Treatment More
• Ironwood to Considers Merger Opportunities After FDA Setback More* More* More
  
• 'One of the Lucky Few': Bicara’s CEO on Operating in Today’s Market, While Hoping for a Different One More
• Scientists Engineer Bacteria to Produce Sensor Molecules That Can be Detected 90 Meters Away More
  
• Subscribe to LifeSci Startup for Updates on US Startups More

Companies

Career Center

• OPPORTUNITY: Chief Executive Officer More
  
• OPPORTUNITY: Chief Product Officer More
• OPPORTUNITY: Vice President, Digital Health Business Development More
• OPPORTUNITY: Chief Business Officer More
• OPPORTUNITY: Vice President, Finance More
• OPPORTUNITY: Director, Compliance & Quality Systems More
• OPPORTUNITY: West Coast Business Development Director More
• OPPORTUNITY: Chief Financial Officer More

Event Center

• BioLabs Investor Day 2025 April 22
  
• Financial Literacy for Life Science Professionals (California) April 22
• Financial Literacy for Life Science Professionals (Capital Region) April 22
• LEAP HR: Life Sciences West April 22-24
  
• Financial Literacy for Life Science Professionals (California) April 23
• Financial Literacy for Life Science Professionals (Philadelphia) April 23
• Financial Literacy for Life Science Professionals (Seattle) April 23
• Life Science Innovation Northwest 2025 April 23-24
• Financial Literacy for Life Science Professionals (Boston) April 24
• Financial Literacy for Life Science Professionals (New York City) April 24
• Milken Institute Global Conference May 4-7
• Seattle Life Sciences Conference May 6
• 2025 JLABS Investor & Partnering Day May 7
• 2025 PEGS Boston Summit May 12-16
• STAT Breakthrough Summit West May 14
• Digital Healthcare Innovation Summit May 19-20
  

Boston Sponsors